Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul:6:e2200040.
doi: 10.1200/CCI.22.00040.

Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set

Affiliations

Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set

Stephanie T Schmidt et al. JCO Clin Cancer Inform. 2022 Jul.

Abstract

Purpose: Advances in biological measurement technologies are enabling large-scale studies of patient cohorts across multiple omics platforms. Holistic analysis of these data can generate actionable insights for translational research and necessitate new approaches for data integration and mining.

Methods: We present a novel approach for integrating data across platforms on the basis of the shared nearest neighbors algorithm and use it to create a network of multiplatform data from the immunogenomic profiling of non-small-cell lung cancer project.

Results: Benchmarking demonstrates that the shared nearest neighbors-based network approach outperforms a traditional gene-gene network in capturing established interactions while providing new ones on the basis of the interplay between measurements from different platforms. When used to examine patient characteristics of interest, our approach provided signatures associated with and new leads related to recurrence and TP53 oncogenotype.

Conclusion: The network developed offers an unprecedented, holistic view into immunogenomic profiling of non-small-cell lung cancer, which can be explored through the accompanying interactive browser that we built.

PubMed Disclaimer

Conflict of interest statement

Alexandre ReubenHonoraria: Adaptive BiotechnologiesConsulting or Advisory Role: Adaptive Biotechnologies Natalie VokesHonoraria: SanofiConsulting or Advisory Role: Sanofi/Regeneron, OncoCyte, LillyResearch Funding: OncoCyte Junya FujimotoConsulting or Advisory Role: Sakura Finetek Japan, ReasonWhy Lauren A. ByersHonoraria: UpToDate, Clinical Care OptionsConsulting or Advisory Role: Merck Sharp & Dohme Corp, Arrowhead Pharmaceuticals, Chugai Pharma, AstraZeneca, Genetech Inc, AbbVie, BeiGene, Jazz PharmaceuticalsResearch Funding: AstraZeneca (Inst), Amgen (Inst), Jazz Pharmaceuticals (Inst)Patents, Royalties, Other Intellectual Property: Pending patents on biomarkers for lung cancer (eg, methods of selection of patients for treatment and novel biomarker tests)—recipient would be my institution and self Lorenzo FedericoResearch Funding: Obsidian Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: Charles River Laboratories. Agreement for the commercialization of transplantable tumor lines Marie-Andree ForgetConsulting or Advisory Role: Proteios TechnologyPatents, Royalties, Other Intellectual Property: License to Obsidian Therapeutics Daniel J. McGrailPatents, Royalties, Other Intellectual Property: Pending patents on biomarkers for sensitivity to cancer therapeutics Younghee LeeEmployment: MD Anderson Cancer Center Jeffrey J. KovacsEmployment: Aktis OncologyStock and Other Ownership Interests: Aktis OncologyPatents, Royalties, Other Intellectual Property: I was the recipient of a royalty payment from an agreement between Ipsen and the MD Anderson Cancer Center pertaining to the licensing and development of IACS-6274/IPN60090 Ignacio I. WistubaConsulting or Advisory Role: Genentech/Roche, Bristol Myers Squibb, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneca/MedImmune, GlaxoSmithKline, Guardant Health, Merck, MSD Oncology, Bayer, OncoCyte, Flame Biosciences, Amgen, Novartis, Daiichi Sankyo/Lilly, Daiichi Sankyo/Astra Zeneca, SanofiSpeakers' Bureau: Pfizer, MSD Oncology, Roche, Merck, AstraZeneca, Daiichi Sankyo/LillyResearch Funding: Genentech (Inst), Merck (Inst), HTG Molecular Diagnostics (Inst), Adaptimmune (Inst), EMD Serono (Inst), Pfizer (Inst), MedImmune (Inst), Takeda (Inst), Karus Therapeutics (Inst), Amgen (Inst), 4D Molecular Therapeutics (Inst), Bayer (Inst), Novartis (Inst), Guardant Health (Inst), Adaptive Biotechnologies (Inst), Johnson & Johnson (Inst), Iovance Biotherapeutics (Inst), Akoya Biosciences (Inst), Sanofi (Inst) Andrew FutrealStock and Other Ownership Interests: Scorpion Therapeutics Ara VaporciyanTravel, Accommodations, Expenses: AstraZeneca Boris SepesiConsulting or Advisory Role: Bristol Myers Squibb/Medarex, AstraZeneca, MedscapeSpeakers' Bureau: AstraZeneca, PeerViewTravel, Accommodations, Expenses: PeerView John V. HeymachStock and Other Ownership Interests: Cardinal Spine, Bio-TreeConsulting or Advisory Role: AstraZeneca, Bristol Myers Squibb, Spectrum Pharmaceuticals, Guardant Health, Hengrui Pharmaceutical, GlaxoSmithKline, EMD Serono, Takeda, Sanofi/Aventis, Genentech/Roche, Boehringer Ingelheim, Mirati Therapeutics, Janssen, Nexus Health Systems, Pneuma Respiratory, Lilly (Inst)Speakers' Bureau: IDEOlogy Health, MJH Life SciencesResearch Funding: AstraZeneca (Inst), Spectrum Pharmaceuticals, GlaxoSmithKlinePatents, Royalties, Other Intellectual Property: Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations Chantale BernatchezEmployment: Cell Therapy Manufacturing CenterStock and Other Ownership Interests: Myst TherapeuticsConsulting or Advisory Role: Myst TherapeuticsResearch Funding: Iovance Biotherapeutics, Obsidian Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy, Patent pending—Methods for expansion of Tumor-Infiltrating Lymphocytes and use thereof, Patent pending—Human 4-1BB agonist antibodies and methods of use thereofExpert Testimony: Allogene Therapeutics Cara HaymakerStock and Other Ownership Interests: BriaCellConsulting or Advisory Role: NanobiotixResearch Funding: Idera (Inst), Iovance Biotherapeutics (Inst), Dragonfly Therapeutics (Inst), Sanofi (Inst), BTG (Inst)Patents, Royalties, Other Intellectual Property: Patent Appl No. 62/977, 672 (Inst) Tina CasconeHonoraria: Society for Immunotherapy of Cancer, Roche, Bristol Myers Squibb, Medscape, PeerViewConsulting or Advisory Role: MedImmune, Bristol Myers Squibb, Genentech, EMD Serono, AstraZeneca, Merck, Arrowhead PharmaceuticalsResearch Funding: Bristol Myers Squibb (Inst), Boehringer Ingelheim (Inst), EMD Serono (Inst), MedImmune (Inst), AstraZeneca (Inst)Travel, Accommodations, Expenses: Parker Institute for Cancer Immunotherapy Jianjun ZhangHonoraria: Roche, Sino-USA Biomedical Platform, Geneplus, OrigiMed, Innovent Biologics, CancerNet, Zhejiang Cancer Hospital, Innovent Biologics, Zhejiang Cancer Hospital, Suzhou Medical Association, Hengrui MedicineConsulting or Advisory Role: AstraZeneca, Geneplus, Capital Medical University, Johnson & Johnson/Janssen, Novartis, Hunan Cancer HospitalResearch Funding: Merck, NovartisTravel, Accommodations, Expenses: Innovent Biologics, Zhejiang Cancer Hospital Timothy P. HeffernanStock and Other Ownership Interests: Cullgen, Roivant DiscoveryConsulting or Advisory Role: Cullgen, Roivant Discovery, Silicon TherapeuticsResearch Funding: Boehringer Ingelheim (Inst), Taiho Pharmaceutical (Inst), Blueprint Medicines (Inst), Schrodinger (Inst)Patents, Royalties, Other Intellectual Property: I am a coinventor on material and method of use patents for therapeutics developed within MD Anderson. I may personally benefit from milestone and royalty agreements through MDA alliances and out-license agreementsTravel, Accommodations, Expenses: Cullgen, Roivant Marcelo V. NegraoConsulting or Advisory Role: Mirati Therapeutics, MerckResearch Funding: Mirati Therapeutics, AstraZeneca, Novartis, Pfizer, ZIOPHARM Oncology, Checkmate Pharmaceuticals, Genentech, Alaunos TherapeuticsOther Relationship: ZIOPHARM Oncology, Apothecom, Ashfield Healthcare Don L. GibbonsStock and Other Ownership Interests: Exact Sciences, NektarConsulting or Advisory Role: Sanofi, GlaxoSmithKline, Janssen Research & Development, Ribon Therapeutics, Mitobridge, Lilly, Menarini, Napa TherapeuticsResearch Funding: Janssen Research & Development, Takeda, AstraZeneca, Mitobridge, Ribon Therapeutics, Boehringer Ingelheim (Inst), Mirati Therapeutics (Inst), NGM BiopharmaceuticalsTravel, Accommodations, Expenses: AstraZeneca/MedImmune, BerGenBio, TakedaNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
ICON project. (A) Schematic of data collected at the time of surgery through the ICON project. Red denotes tumor samples, and white denotes adjacent uninvolved tissue samples. (B) Heatmap of measurements available in ICON for each platform (rows) across patients (columns). Colors indicate treatment received, stage, histology, and data availability. FC, flow cytometry; ICON, immunogenomic profiling of non–small-cell lung cancer; mIF, multiplex immunofluorescence; NSCLC, non–small-cell lung cancer; RNA-Seq, RNA sequencing; RPPA, reverse phase protein array; TCR-seq, T-cell receptor sequencing; WES, whole-exome sequencing.
FIG 2.
FIG 2.
SNN drives integrated ICON data network. (A) Overlap score is determined by the fraction of shared top k correlates from RPPA, FC. (B) SNN matrix is compiled by performing scoring across all gene pairs for RPPA, FC. (C) Gene pairs meeting score threshold are used to construct the overall network. FC, flow cytometry; ICON, immunogenomic profiling of non–small-cell lung cancer; RPPA, reverse phase protein array; SNN, shared nearest neighbors.
FIG 3.
FIG 3.
ICON data network combines SNN with RNA-based correlation edges. (A) Selection of SNN with RNA-based edges on the basis of improved performance over SNN, RNA alone. (B) Community detection via Infomap identifies 10 top-level modules and 93 mid-level modules with at least 10 genes. The modules can be examined in tandem with orthogonal data modalities and patient characteristics. (C) Overview of the ICON data network composition. For each top-level module, the most significant annotation (with specific database source in parentheses where applicable) of its mid-level modules is shown. Modules in gray are without annotations meeting FDR < 0.05. (D) Nodes balanced across source modalities. Overlaps in gene nodes from each modality shown along with representative summary annotations. (E) SNN modalities provide more edges per node. Overlaps in network edges from each modality shown. ECM, extracellular matrix; FC, flow cytometry; FDR, false discovery rate; ICON, immunogenomic profiling of non–small-cell lung cancer; KEGG, Kyoto Encyclopedia of Genes and Genomes; PID, Pathway Interaction Database; RPPA, reverse phase protein array; SNN, shared nearest neighbors.
FIG 4.
FIG 4.
ICON data browser enables exploration of ICON data and network. (A) The network panel offers a view into the multilayered structures of constituent modules, pathway annotation results, and top correlates from the shared nearest neighbors-based network-building approach tied to module formation. (B) The plotting and modeling panel allows for a selected module's ssGSEA scores or any other measurement across the full ICON data set to be compared against categorical metadata or against a secondary continuous measurement. FDR, false discovery rate; ICON, immunogenomic profiling of non–small-cell lung cancer; KEGG, Kyoto Encyclopedia of Genes and Genomes; N/A, not available; PID, Pathway Interaction Database; RPPA, reverse phase protein array; ssGSEA, single sample gene set enrichment; TID, tumor identifer.
FIG 5.
FIG 5.
Network mining identifies module strongly tied to patient recurrence. (A) Distribution of ssGSEA scores by patient response for the neoadjuvant-free cohort. (B) Distribution of ssGSEA scores by patient response for a subset of cohort with nonsquamous, stage II+ tumors. (C) Top pathways for genes driving annotation of the selected module with the false discovery rate < 0.25. (D) Correlation of module scores with the Morisita overlap index from T-cell receptor sequencing (ϱ = 0.53, P = 1.98e–05). ssGSEA, single sample gene set enrichment.
FIG 6.
FIG 6.
Network mining identifies the transfer RNA–focused module strongly associated with functionally significant TP53 mutations in LUSC. (A) Distribution of ssGSEA scores by TP53 status for LUSC tumors. (B) Correlation of module scores with the presence of malignant cells (count/mm2) in the tumor and stroma via multiplex immunofluorescence (ϱ = 0.55, P = 6.39e–03). (C) Components of the identified module highlight strength of interaction with transfer RNA transcripts. LUSC, lung squamous cell carcinoma; ssGSEA, single sample gene set enrichment.

Similar articles

Cited by

  • Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
    Konen JM, Rodriguez BL, Wu H, Fradette JJ, Gibson L, Diao L, Wang J, Schmidt S, Wistuba II, Zhang J, Gibbons DL. Konen JM, et al. J Clin Invest. 2023 Sep 1;133(17):e163128. doi: 10.1172/JCI163128. J Clin Invest. 2023. PMID: 37655662 Free PMC article.
  • CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
    Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hell… See abstract for full author list ➔ Skoulidis F, et al. Nature. 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9. Nature. 2024. PMID: 39385035 Free PMC article.
  • Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept.
    Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Salehjahromi M, et al. Cell Rep Med. 2024 Mar 19;5(3):101463. doi: 10.1016/j.xcrm.2024.101463. Epub 2024 Mar 11. Cell Rep Med. 2024. PMID: 38471502 Free PMC article.
  • ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Treviño S 3rd, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. Vokes NI, et al. Clin Cancer Res. 2023 Dec 1;29(23):4958-4972. doi: 10.1158/1078-0432.CCR-23-1122. Clin Cancer Res. 2023. PMID: 37733794 Free PMC article.
  • EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.
    Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. Xiao GY, et al. Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2220276120. doi: 10.1073/pnas.2220276120. Epub 2023 Jul 5. Proc Natl Acad Sci U S A. 2023. PMID: 37406091 Free PMC article.

References

    1. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. : The cancer genome atlas Pan-cancer analysis project. Nat Genet 45:1113-1120, 2013 - PMC - PubMed
    1. AACR Project GENIE Consortium : AACR project GENIE: Powering precision medicine through an International Consortium. Cancer Discov 7:818-831, 2017 - PMC - PubMed
    1. Cerami E, Gao J, Dogrusoz U, et al. : The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012 - PMC - PubMed
    1. Gomez-Cabrero D, Abugessaisa I, Maier D, et al. : Data integration in the era of omics: Current and future challenges. BMC Syst Biol 8:I1, 2014. (suppl 2) - PMC - PubMed
    1. Huang S, Chaudhary K, Garmire LX: More is better: Recent progress in multi-omics data integration methods. Front Genet 8:84, 2017 - PMC - PubMed

Publication types